ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2584

Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial

Philip Mease1, Alan Kivitz2, Elena Muensterman3, Apinya Lertratanakul4, Ting Hong4, Jingjing Chen4, Ejim Mark5 and Xenofon Baraliakos6, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Altoona Center for Clinical Research, Duncansville, PA, 3Takeda Development Center Americas, Cambridge, MA, 4Takeda Development Center Americas, Inc., Cambridge, MA, 5Takeda Development Center Americas Inc., Cambridge, 6Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany

Meeting: ACR Convergence 2024

Keywords: clinical trial, Psoriatic arthritis, Randomized Trial

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: SpA Including PsA – Treatment II

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Zasocitinib (TAK-279) is an oral, selective TYK2 inhibitor under investigation for the treatment of immune-mediated inflammatory diseases including psoriatic arthritis (PsA). In a phase 2b trial in patients with active PsA (NCT05153148), 12-week ACR20 response rates were significantly greater among patients receiving zasocitinib 15 or 30 mg once daily (QD) than those receiving placebo (PBO, primary endpoint; p=0.002).1 PsA treat-to-target recommendations state that the treatment target should be remission or low disease activity (LDA);2 here, additional disease activity data are presented.

Methods: This was a phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study. Patients (18–70 years) with active PsA were randomized 1:1:1:1 to receive oral zasocitinib 5, 15 or 30 mg QD or PBO for 12 weeks.1 Secondary endpoints included change from baseline (BL) to Week 12 in Disease Activity Index for PsA (DAPSA). Exploratory endpoints included changes from BL to Week 12 in PsA Disease Activity Score (PASDAS) and Disease Activity Score 28 with high-sensitivity C-reactive protein (DAS28-hsCRP), and the proportion of patients achieving improvements in PsA Response Criteria (PsARC) at Week 12. Differences were assessed using a Mantel–Haenszel test (binary endpoints) and a mixed model for repeated measures (continuous endpoints). All p values are nominal.

Results: In total, 290 patients were randomized and treated. BL disease characteristics were generally comparable across groups; mean (standard deviation; SD) PsA disease duration was 6.9 (7.1) years and mean hsCRP level was 7.0 (12.2) mg/L. Mean (SD) tender joint count and DAPSA at BL were lower in the zasocitinib 30 mg arm (14.0 [9.4] and 33.4 [15.8], respectively) than in the PBO (18.5 [14.7] and 38.3 [20.7], respectively), zasocitinib 5 mg (18.4 [15.2] and 39.0 [21.6], respectively) and zasocitinib 15 mg (18.0 [12.8] and 40.1 [18.0], respectively) arms. Greater numbers of patients receiving zasocitinib 15 or 30 mg than those receiving PBO or zasocitinib 5 mg were considered in remission or achieved LDA at Week 12, as measured using DAPSA, PASDAS and DAS28-hsCRP (Table 1). Least-squares mean changes from BL to Week 12 in DAPSA, PASDAS and DAS28-hsCRP were generally greater in patients receiving zasocitinib than in those receiving PBO, at all doses tested (Figure 1). Compared with PBO, patients receiving zasocitinib 15 or 30 mg had greater reductions in DAPSA (–17.99 [p=0.018] and –16.79 [p=0.056], respectively), PASDAS (–1.91 [p< 0.001] and –1.75 [p=0.001], respectively) and DAS28-hsCRP (–1.20 [p=0.002] and –1.15 [p=0.006], respectively) at Week 12. At Week 12, a numerically higher proportion of patients receiving zasocitinib 15 mg or 30 mg achieved a PsARC response versus those receiving PBO (p=0.024 and p=0.140, respectively).

Conclusion: Treatment with zasocitinib 15 and 30 mg resulted in higher rates of remission or LDA after 12 weeks in patients with PsA compared with placebo. Zasocitinib shows promise as a novel oral therapy in PsA and warrants further investigation in phase 3 trials.

References:

1. Kivitz A et al. Arthritis Rheumatol 2023;75 (Suppl 9).

2. Gossec L et al. Ann Rheum Dis 2024;83:706–19.

Supporting image 1

Supporting image 2


Disclosures: P. Mease: AbbVie, 2, 5, Aclaris Therapeutics, 2, 5, Aclyrin, 2, 5, Amgen, 2, 5, Boehringer Ingelheim, 2, 5, Bristol Myers Squibb, 2, 5, CorEvitas, 2, 5, Galápagos, 2, 5, Gilead, 2, 5, Inmagene, 2, 5, Janssen, 2, 5, Lilly, 2, 5, MoonLake Immunotherapeutics, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Sun Pharma, 2, 5, UCB, 2, 5; A. Kivitz: AbbVie, 2, 6, Amgen, 6, 11, Coval, 2, Ecor1, 2, Fresenius Kabi, 2, Genzyme, 12, Scientific ExpertGenzyme, Gilead, 2, 11, GlaxoSmithKlein (GSK), 2, 6, 11, Grunenthal, 2, Horizon, 2, Innovaderm, 2, Janssen, 2, Lilly, 6, Novartis, 11, Pfizer, 6, 11, Prime, 12, Educational, Prometheus, 2, Sanofi - Regeneron, 6, SynAct, 2, Takeda, 2, UCB, 2, 6, XBiotech, 2; E. Muensterman: Takeda, 3, 11; A. Lertratanakul: Takeda, 3, 11; T. Hong: Takeda, 3, 11; J. Chen: Takeda, 3, 11; E. Mark: Takeda, 3, 11; X. Baraliakos: AbbVie, 2, 5, 6, Bristol-Myers Squibb (BMS), 2, 5, 6, Celgene, 2, 5, 6, Chugai, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6.

To cite this abstract in AMA style:

Mease P, Kivitz A, Muensterman E, Lertratanakul A, Hong T, Chen J, Mark E, Baraliakos X. Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/zasocitinib-tak-279-an-oral-selective-tyrosine-kinase-2-inhibitor-achievement-of-remission-and-additional-improvements-in-disease-activity-in-patients-with-psoriatic-arthritis-enrolled-in-a-phase/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/zasocitinib-tak-279-an-oral-selective-tyrosine-kinase-2-inhibitor-achievement-of-remission-and-additional-improvements-in-disease-activity-in-patients-with-psoriatic-arthritis-enrolled-in-a-phase/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology